A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

• Status: RECRUITING
• Trial end date: 2030-02-01

Summary

Phase 1 first-in-human, open-label, dose-escalation (3 + 3), dose-expansion clinical trial to evaluate the safety, tolerability and preliminary clinical efficacy of M3T01 (fully human IgG4/kappa monoclonal antibody targeting FasL) in subjects with metastatic or unresectable solid tumors.

• Phase: PHASE1

Details

• Lead Sponsor: Providence Health & Services
• Treatments: Chemoradiotherapy; Fluorouracil; Folfox protocol; Leucovorin; Oxaliplatin; pembrolizumab